Evaluation of the effects of Dapaglifozin on liver on patients with Type 2 Diabetes Mellitus and Metabolic liver disease
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Registration Number
- CTRI/2023/03/050799
- Lead Sponsor
- Department of medicine Jawaharlal Nehru medical college and hospital AMU Aligarh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Diagnosed type 2 DM patients on standard treatment for diabetes whether be it Insulin or oral hypoglycemic agents except all SGLT2 Inhibitors
2. Patients diagnosed with NAFLD made on the basis of history of low daily alcohol intake ( < 30 g for men and < 20 g for women), liver biochemistry, presence of fatty liver on ultrasonography and transient elastography.
3. Patients giving informed consent
1. Patients with other causes of chronic liver disease like chronic viral hepatitis, autoimmune hepatitis, excessive alcoholic consumption, drug-induced liver injury, biliary tract disease, decompensated liver cirrhosis, hepatocellular carcinoma, history of diabetic ketoacidosis
2. Patients with co-administration of medications that may affect liver function tests (such as NSAIDS, Vitamin E, pioglitazone, saroglitazar, statin, and TZDs)
3. Presence of severe comorbidities such as CAD, CHF, CKD, COPD, pyelonephritis and chronic UTI
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method